Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices.

[1]  Kirsten L. Greene,et al.  Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. , 2015, The Journal of urology.

[2]  David C. Miller,et al.  Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.

[3]  David C. Miller,et al.  Toward better use of bone scans among men with early-stage prostate cancer. , 2014, Urology.

[4]  Robert J Volk,et al.  Physician variation in management of low-risk prostate cancer: a population-based cohort study. , 2014, JAMA internal medicine.

[5]  David C. Miller,et al.  Variation in prostate cancer detection rates in a statewide quality improvement collaborative. , 2014, The Journal of urology.

[6]  C. Gross,et al.  Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists , 2014, Medical care.

[7]  David C. Miller,et al.  Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative. , 2014, The Journal of urology.

[8]  M. Cooperberg,et al.  Active surveillance for prostate cancer: a systematic review of the literature. , 2012, European urology.

[9]  T. Skolarus,et al.  Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. , 2012, Health affairs.

[10]  G. Andriole.  Active Surveillance for the Management of Prostate Cancer in a Contemporary Cohort: Dall'Era MA, Konety BR, Cowan JE, et al (Univ of California at San Francisco; et al) Cancer 112:2664-2670, 2008 § , 2012 .

[11]  A. Shalhav,et al.  Gleason 6 prostate cancer in one or two biopsy cores can harbor more aggressive disease. , 2011, Journal of endourology.

[12]  A. Billis.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience , 2011 .

[13]  S. Greenfield,et al.  Overtreatment of men with low‐risk prostate cancer and significant comorbidity , 2011, Cancer.

[14]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Cooperberg,et al.  Active surveillance for the management of prostate cancer in a contemporary cohort , 2008, Cancer.

[17]  B. Guillonneau,et al.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. , 2008, The Journal of urology.

[18]  John T. Wei,et al.  Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. , 2006, Journal of the National Cancer Institute.

[19]  L. Klotz.  Active surveillance for prostate cancer: for whom? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.